Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (31-40 of 222) with videos related to

Pageof 23
Sort By:
Plos One|November 13, 2012
NLK is a novel therapeutic target for PTEN deficient tumour cellsAna M Mendes-Pereira, Christopher J Lord, Alan Ashworth
Cancer Research|November 16, 2021
PARP Inhibitors - Trapped in a Toxic Love AffairDragomir B Krastev, Andrew J Wicks, Christopher J Lord
Cell|April 5, 2011
Genetic interactions in cancer progression and treatmentAlan Ashworth, Christopher J Lord, Jorge S Reis-Filho
The Journal of Pathology|November 6, 2009
Genomic instability and the selection of treatments for cancerSarah A Martin, Madeleine Hewish, Christopher J Lord, et al.
Cell Systems|July 17, 2017
CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in CancerStephen Bridgett, James Campbell, Christopher J Lord, et al.
Endocrine-Related Cancer|August 17, 2016
Synthetic lethality: the road to novel therapies for breast cancerKiranjit K Dhillon, Ilirjana Bajrami, Toshiyasu Taniguchi, et al.
Human Molecular Genetics|August 21, 2003
Phenotypic effects of heterozygosity for a BRCA2 mutationMadhuri Warren, Christopher J Lord, Julio Masabanda, et al.
DNA Repair|April 11, 2013
Identification of miRNA modulators to PARP inhibitor responseSari Neijenhuis, Ilirjana Bajrami, Rowan Miller, et al.
Hematology/Oncology Clinics of North America|November 26, 2022
Systemic Therapy for Hereditary Breast CancersElizabeth J Harvey-Jones, Christopher J Lord, Andrew N J Tutt
Molecular Oncology|May 14, 2022
Resistance to DNA repair inhibitors in cancerJoseph S Baxter, Diana Zatreanu, Stephen J Pettitt, et al.
Pageof 23

Showing results (31-40 of 222) with videos related to

Sort By:
Pageof 23
Plos One|November 13, 2012
NLK is a novel therapeutic target for PTEN deficient tumour cellsAna M Mendes-Pereira, Christopher J Lord, Alan Ashworth
Cancer Research|November 16, 2021
PARP Inhibitors - Trapped in a Toxic Love AffairDragomir B Krastev, Andrew J Wicks, Christopher J Lord
Cell|April 5, 2011
Genetic interactions in cancer progression and treatmentAlan Ashworth, Christopher J Lord, Jorge S Reis-Filho
The Journal of Pathology|November 6, 2009
Genomic instability and the selection of treatments for cancerSarah A Martin, Madeleine Hewish, Christopher J Lord, et al.
Cell Systems|July 17, 2017
CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in CancerStephen Bridgett, James Campbell, Christopher J Lord, et al.
Endocrine-Related Cancer|August 17, 2016
Synthetic lethality: the road to novel therapies for breast cancerKiranjit K Dhillon, Ilirjana Bajrami, Toshiyasu Taniguchi, et al.
Human Molecular Genetics|August 21, 2003
Phenotypic effects of heterozygosity for a BRCA2 mutationMadhuri Warren, Christopher J Lord, Julio Masabanda, et al.
DNA Repair|April 11, 2013
Identification of miRNA modulators to PARP inhibitor responseSari Neijenhuis, Ilirjana Bajrami, Rowan Miller, et al.
Hematology/Oncology Clinics of North America|November 26, 2022
Systemic Therapy for Hereditary Breast CancersElizabeth J Harvey-Jones, Christopher J Lord, Andrew N J Tutt
Molecular Oncology|May 14, 2022
Resistance to DNA repair inhibitors in cancerJoseph S Baxter, Diana Zatreanu, Stephen J Pettitt, et al.
Pageof 23